Litcius/Paper detail

2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice

Javier Rodríguez‐Carrio, Agata Burska, Philip G. Conaghan, Willem A. Dik, Robert Biesen, Maija‐Leena Eloranta, Giulio Cavalli, Marianne E Visser, Dimitrios T. Boumpas, George Βertsias, Marie Wahren‐Herlenius, Jan Rehwinkel, Marie‐Louise Frémond, Mary K. Crow, Lars Rönnblom, Marjan A. Versnel, Edward M Vital

2023Annals of the Rheumatic Diseases40 citationsDOIOpen Access PDF

Topics & Concepts

MedicineTerminologyClinical PracticeClinical diseaseEvidence-based medicineClinical researchTranslational researchTask forceMedical physicsAlternative medicineIntensive care medicineDiseasePathologyPhysical therapyPublic administrationLinguisticsPolitical sciencePhilosophyRheumatoid Arthritis Research and TherapiesSystemic Lupus Erythematosus ResearchAutoimmune and Inflammatory Disorders Research
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice | Litcius